NAPSR News: Shire will acquire NPS Pharmaceuticals for $5.2 billion

Jan. 12, 2015 - PRLog -- Shire will acquire NPS Pharmaceuticals for $46.00 per share in cash amounting to approximately $5.2 billion. The acquisition will give Shire access to NPS Pharma’s gastrointestinal (GI) disorders portfolio and rare disease pipeline. Shire expects to see a boost in revenue from NPS Pharma’s first product GATTEX®/REVESTIVE® (teduglutide [rDNA origin]) which is approved in the United States and Europe to treat short bowel syndrome (SBS) who are dependent on parenteral support. NPS Pharma’s NATPARA®/NATPAR® (rhPTH -83) granted orphan drug status by the FDA is pending regulatory approval for the treatment of hypoparathyroidism (HPT).

Shire’s Chief Executive Officer, Flemming Ornskov, MD, MPH, commented: “The acquisition of NPS Pharma is a significant step in advancing Shire’s strategy to become a leading biotechnology company. With our global strength and expertise in both rare diseases and GI, Shire is uniquely positioned to drive the continued success of GATTEX/REVESTIVE, and, if approved, commercialize NPS Pharma’s pipeline compound NATPARA/NATPAR. We look forward to accelerating the growth of the NPS Pharma portfolio based on our proven track record of maximizing value from acquired assets and commercial execution. The NPS Pharma organization will be a welcome addition to Shire as we continue to help transform the lives of patients with rare diseases.”

Francois Nader, MD, President, Chief Executive Officer and Director of NPS Pharma, stated:
“Shire shares NPS Pharma’s commitment to patients with rare diseases. We believe that joining our two companies will drive value for shareholders and ensure we continue to transform the lives of patients with short bowel syndrome, hypoparathyroidism, and autosomal dominant hypocalcemia worldwide. I am confident that this transaction will accelerate our ambition of creating a world where every person living with a rare disease has a therapy. I would like to thank all of our employees for their continued outstanding contributions and steadfast commitment to the patients we serve.”

ABOUT US

The NAPSRx® is a trade association for pharmaceutical sales reps, sales managers and sales trainers who work in the pharmaceutical industry. NAPSRx® provides Continuing Medical Education to its members as well as CNPR® Certification to candidates who look to enter a pharmaceutical sales career. The CNPR is a federally trademarked certification you can earn by demonstrating the necessary knowledge in pharmacology, medical terminology, physiology, and regulations for selling pharmaceuticals.

The CNPR® Program represents a level of industry achievement and a demonstrated knowledge of pharmacology, medical terminology, pharmaceutical selling guidelines, physician selling techniques and industry standards. Upon successful completion of the training each student will receive the Certification Mark of the CNPR®.
Individuals that are interested in becoming a Certified National Pharmaceutical Representative (CNPR) can contact the National Association of Pharmaceutical Sales Representatives(NAPSRx) for more information or visit the website at http://napsronline.org/ (http://napsronline.org/)